Omeros's Total Assets for the quarter that ended in Dec. 2024 was $277.08 Mil.
During the past 12 months, Omeros's average Total Assets Growth Rate was -9.40% per year.
During the past 3 years, the average Total Assets Growth Rate was -10.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 30.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 46.00% per year.
During the past 13 years, Omeros's highest 3-Year average Total Assets Growth Rate was 108.10%. The lowest was -13.10%. And the median was 34.00%.
Total Assets is connected with ROA %. Omeros's annualizedROA % for the quarter that ended in Dec. 2024 was -42.49%. Total Assets is also linked to Revenue through Asset Turnover. Omeros's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.
Omeros Total Assets Historical Data
The historical data trend for Omeros's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Omeros's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Omeros's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Omeros Total Assets Related Terms
Thank you for viewing the detailed overview of Omeros's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OMER has been successfully added to your 